Why Wall Street Thinks BioNTech Stock Could Sink 25%
BioNTech (NASDAQ: BNTX) might not be the best-known of the leading COVID-19 vaccine makers. The company has been largely overshadowed by its big partner Pfizer and by Moderna, at least in the U.S. However, BioNTech has been the biggest winner in the group so far this year with its shares skyrocketing more than 350%.
But that impressive gain could be a precarious one, based on analysts' projections. Here's why Wall Street thinks BioNTech stock could sink 25% within the next 12 months.
Image source: Getty Images.
Source Fool.com